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A B S T R A C T   
The goal of hormone replacement is to mirror physiology. Hydrocortisone granules and modified release for-
mulations are being developed to optimise cortisol replacement in the rare disease of adrenal insufficiency. To 
facilitate clinical development, we built and verified a physiologically based pharmacokinetic (PBPK) model for 
the endogenous hormone cortisol (hydrocortisone) in healthy adults, and children and adults with adrenal 
insufficiency. 
The model predicted immediate-release hydrocortisone pharmacokinetics in adults across the dose range 0.5 
to 20 mg, with predicted/observed AUCs within 0.8 to 1.25-fold.  The model also tightly predicted pharmaco-
kinetic parameters for modified-release formulations, with AUCs within 0.8 to 1.25-fold after single and multiple 
dosing.  Predicted modified-release formulation pharmacokinetics (PK) in 12 to 18-year olds showed PK to be 
similar to adults. 
This hydrocortisone PBPK model is a useful tool to predict adult and paediatric pharmacokinetics of both 
immediate- and modified-release hydrocortisone formulations, and develop clinical dosing regimens.   
1. Introduction 
Cortisol is an essential adrenal glucocorticoid stress hormone, 
regulated by the pituitary and has a distinct circadian rhythm (Bancos 
et al., 2015). Diseases of cortisol deficiency, called adrenal insufficiency, 
are rare, resulting in an adrenal crisis and ultimately death if patients are 
not adequately treated. Adrenal insufficiency can be congenital or ac-
quired and once diagnosed is a life-long condition. In childhood, the 
genetic condition congenital adrenal hyperplasia (CAH) is the com-
monest cause of adrenal deficiency, and in adults it can be either pri-
mary, due to failure of the adrenal gland (Addison’s Disease), or 
secondary due to failure of the pituitary gland to stimulate the adrenal 
(hypopituitarism). 
For both CAH and adrenal insufficiency, glucocorticoid replacement 
therapy is primarily with hydrocortisone (identical to the endogenous 
cortisol molecule) which is given multiple times a day due to its short 
half-life. In neonates early diagnosis and individualised treatment with 
hydrocortisone two to four times daily is vital to ensure survival and 
prevent poor health outcomes (Merke and Bornstein, 2005). The chal-
lenge for the paediatrician treating young children with CAH is to 
maintain a balance between too little hydrocortisone, with the risk of 
adrenal crisis, and too much, resulting in growth suppression, hyper-
tension and obesity. This risk is increased when no paediatric appro-
priate formulation is available, with children dependent on 
compounded tablets which, one detailed study reported, in up to 25% of 
tested batches prescribed to paediatric patients, did not meet the Eu-
ropean Pharmacopeia accuracy and precision criteria (Neumann et al., 
2017). Recently, a taste-masked multi-particulate formulation of hy-
drocortisone (Infacort®), with paediatric appropriate doses, has been 
developed and is licensed in the European Union under the trade name 
Alkindi® (hydrocortisone granules in capsules for opening) (Diurnal 
Europe B.V., Netherlands)(Neumann et al., 2020; Neumann et al., 2018; 
Whitaker et al., 2015). Carrying out clinical studies in children is chal-
lenging and, in the absence of detailed paediatric clinical data, the 
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development of a PBPK model could better inform clinicians of how best 
to tailor the dose of hydrocortisone to the child as it grows. 
The cortisol circadian rhythm is established early in life and is 
important for health (Porter et al., 2017). Current hydrocortisone ther-
apy cannot replace the healthy cortisol circadian rhythm and this is a 
problem particularly in patients with CAH as they grow and develop 
because the failure of cortisol levels to rise in the early hours of the 
morning results in poor disease control and poor health outcomes (Han 
et al., 2014). A modified-release hydrocortisone formulation based on 
multi-particulate technology with a delayed release coating (Chro-
nocort®) has been developed to meet the need for a hydrocortisone 
formulation that could reproduce the endogenous cortisol circadian 
rhythm. When given twice daily (ca. 2300 h and ca. 0700 h), this 
modified-release formulation provides cortisol concentrations that 
reflect normal physiology (Whitaker et al., 2014), and improve disease 
control in patients with CAH (Mallappa et al., 2015). To date, clinical 
testing of this modified-release formulation has only been carried out in 
adults and there is a need to predict PK in children, especially adoles-
cents where disease control is poor(Finkielstain et al., 2012). 
PBPK models marry the complex interplay of physiological (system) 
parameters with drug related properties and represent a mechanistic 
approach by which to quantitatively predict the PK of specific drugs in 
different populations (Jamei et al., 2009). Paediatric PBPK (p-PBPK) 
models additionally take into account the development of organs and 
the ontogeny of specific enzymes and transporters that determine age 
related pharmacokinetic (PK) profiles (Johnson and Rostami-Hodjegan, 
2011; Johnson et al., 2006). The overall aim of this study was to develop 
adult and then paediatric PBPK models for the immediate-release, 
multi-particulate and modified-release formulations of hydrocortisone, 
with the ultimate goal of simulating the immediate-release multi--
particulate formulation PK from birth to 18 years and then the 
modified-release PK in adolescents from 12 to 18 years of age (as 
modified-release formulations are generally avoided in younger age 
groups). 
2. Materials and Methods 
2.1. PBPK approach 
The PBPK models for hydrocortisone were developed using the 
Simcyp Simulator population-based PBPK software (Certara UK Ltd., 
Simcyp Division, Sheffield, UK; version 16.1). The development of the 
various models and populations within the Simcyp Simulator has been 
described previously (Jamei et al., 2009; Johnson et al., 2006). The 
strategy for developing the PBPK models for hydrocortisone followed 
the established ‘best practice’ using a ‘Learn and Confirm’ approach 
(Jones and Rowland-Yeo, 2013), and is shown graphically in Figure 1. 
2.1.1. Model-building sequences 
Adult published studies describing the PK of intravenous (IV) hy-
drocortisone were used to establish the initial drug parameters for dis-
tribution and elimination (Derendorf et al., 1991; Toothaker and 
Welling, 1982). Data from published studies describing 
immediate-release oral hydrocortisone PK were then used to establish 
the absorption model parameters for the immediate-release formula-
tions of hydrocortisone, and to provide further verification of the model 
(Derendorf et al., 1991; Toothaker et al., 1982a; Toothaker et al., 
1982b). Once developed, clinical studies of the immediate-release 
multi-particulate formulation in adults (Infacort-001 and Infacort-002; 
EudraCT Number: 2013-000260-28) were used to verify the final 
model before performing simulations in the paediatric population. As-
pects of the immediate-release multi-particulate PBPK model were car-
ried forward into development of the modified-release model, in which 
one clinical study in adults (DIUR-004; EudraCT number: 
Figure 1. Workflow of hydrocortisone model development, verification, and application  
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Table 1 
Mean observed and predicted IV and oral hydrocortisone PK parameters in adults  
Published Clinical studies 
Study Dose (mg) Route AUC0-inf (ng/ml*h) Cmax (ng/ml) Tmax (h) 
Toothaker and Welling (1982) 5 IV 410±80 312±NR - 
Predicted 5 IV 358±108 225±46 - 
Ratio (Pred/Obs)   0.87 0.72  
Toothaker and Welling (1982) 10 IV 790±100 573±NR - 
Predicted 10 IV 641±201 470±184 - 
Ratio (Pred/Obs)   0.81 0.82  
Toothaker and Welling (1982) 20 IV 1480±310 1095±NR - 
Derendorf et al. (1991) 20 IV 1175±285 NR - 
Predicted 20 IV 1229±453 731±284 - 
Ratio (Pred/Obs)   0.83/1.04 0.67/NR  
Toothaker et al. (1982a,b) 5 oral (IR) 293±57 119±23 0.7±0.4 
Predicted 5 oral (IR) 318±105 94.1±23 1.2±0.19 (1.2, range 0.8 to 1.72)* 
Ratio (Pred/Obs)   1.08 0.79  
Toothaker et al. (1982a,b) 10 oral (IR) 474±48 199±29 1.0±0.5 
Toothaker et al. (1982a,b) 10 oral (IR) 447±75 175±119 0.8±0.5 
Predicted 10 oral (IR) 551±171 157±35 1.2±0.19 (1.2, range 0.75 to 1.73)* 
Ratio (Pred/Obs)   1.16/1.23 0.79/0.89  
Derendorf et al., 1991(Derendorf et al., 1991) 20 oral (IR) 1162±308 258±70 1.4±0.3 
Toothaker et al. (1982a,b) 20 oral (IR) 835±148 263±55 0.9±0.5 
Patel et al. (1984) (B) Patel et al. (1984) 20 oral (IR) 911±234 252±40 1.4±0.7 
Patel et al. (1984) (D) Patel et al. (1984) 20 oral (IR) 858±224 285±62 1.0±0.6 
Predicted 20 oral (IR) 933±364 273±111 1.2±0.18 (1.2 range 0.7 to 1.75)* 




Toothaker et al. (1982a,b) 30 oral (IR) 958±113 393±58 1.0±0.5 
Predicted 30 oral (IR) 1367±509 433±188 1.2±0.2 hours (1.2, range 0.45 to 1.7)* 
Ratio (Pred/Obs)   1.42 1.10  
Infacort studies      
Study Dose (mg) Route AUC0-inf (nM*h) Cmax (nM) tmax (h) (median and range) 
Infacort 001 (Melin et al., 2017; Whitaker et al., 2015) 0.5 oral (IRM) 123±28 74.8±19.9 0.5 (0.5 to 1.0) 
Predicted 0.5 oral (IRM) 101±38 43.3±12.9 1.1 (0.7 to 1.5) 
Ratio (Pred/Obs)   0.82 0.58  
Infacort 001 (Melin et al., 2017; Whitaker et al., 2015) 2 oral (IRM) 449±80 228±39 0.5 (0.5 to 1.5) 
Predicted 2 oral (IRM) 374±124 157±44 1.1 (0.7 to 1.5) 
Ratio (Pred/Obs)   0.83 0.69  
Infacort 001 (Melin et al., 2017; Whitaker et al., 2015) 5 oral (IRM) 909±152 404±61 0.5 (0.5 to 1.5) 
Predicted 5 oral (IRM) 813±249 333±85 1.1 (0.8 to 1.5) 
Ratio (Pred/Obs)   0.89 0.82  
Infacort 001 (Melin et al., 2017; Whitaker et al., 2015) 10 oral (IRM) 1603±282 600±138 0.75 (0.5 to 1.5) 
Predicted 10 oral (IRM) 1364±386 537±122 1.1 (0.8 to 1.5), 
Ratio (Pred/Obs)   0.85 0.90  
Infacort 002 (Johnson et al., 2018; Melin et al., 2017) 20 oral (IRM) 2630±714 974±284 0.75 (0.5 to 1.25) 
Predicted 20 oral (IRM) 2165±567 809±172 1.05 (0.5 to 1.5) 
Ratio (Pred/Obs)   0.82 0.82  
Chronocort studies      
Study Dose (mg) Route AUC0-inf (nM*h) Cmax (nM) tmax (h) (median and range) 
DIUR-004 (Karunasena et al., 2017) - Fasted 20 oral (MR) 2981±417 708±135 4.5 (2.5 to 6.5) 
Predicted 20 oral (MR) 2659±771 487±131 3.9 (1.1 to 8.1) 
Ratio (Pred/Obs)   0.89 0.69  
DIUR-004(Karunasena et al., 2017) - Fed 20 oral (MR) 3229±613.5 549±93.3 6.8 (3.5 to 20) 
Predicted 20 oral (MR) 2882±864.6 414±116 4.2 (1.3 to 7.9) 
Ratio (Pred/Obs)   0.89 0.75 0.62 
DIUR-003 (Mallappa et al., 2015) 20/10 oral (MR) 4870±1218 591±112 - 
Predicted 20/10 oral (MR) 4766±1512 551±165 - 
Ratio (Pred/Obs)   0.98 0.93 - 
DIUR-008 20 oral (MR) 2640±634 609±140 5.0 (2.0 to 6.0) 
Predicted 20 oral (MR) 2641±766 474±128 3.83 (1.2 to 8.1) 
Ratio (Pred/Obs)   1.00 0.78  
IV=intravenous; IR=immediate-release; IRM=Infacort® immediate-release multiparticulate form; MR=Chronocort® modified-release form 
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2014-005025-12) was used to further develop the model to be suitable 
for a modified-release formulation. The performance of the 
modified-release PBPK model was then verified using data from two 
additional clinical studies in adults (DIUR-003 and DIUR-008; IND 
number: 76485 & EudraCT number: 2016-001390-32). A summary of 
the studies is presented in Supplementary Table 1. Once verified, the 
modified-release model was used to simulate the PK of both single and 
multiple dosing scenarios in a virtual adolescent population aged 12 to 
18 years. 
PK data are presented as total (free and bound) cortisol. Although 
unbound cortisol is the active form in the body, total concentrations as 
well as pharmacodynamic and clinical endpoints are primarily used for 
dose modification and efficacy evaluation in the clinic. 
2.1.2. Population parameters used in the PBPK models 
2.1.2.1. Absorption parameters. The default gastric residence times 
within Simcyp Simulator were used for simulations of immediate release 
formulations. For modified-release simulations, the fasted mean gastric 
residence time was set to 2 hours to reflect the extended gastric 
emptying time of pellet formulations (Davis et al., 1986). In addition, 
the coefficient of variation (CV) for the pH values of some of the intes-
tinal segments in the model were decreased in order to ensure that the 
release pH for the formulation occurred in all virtual subjects. These 
absorption changes are described further in the Supplementary data – 
Section 1. 
2.1.2.2. Incorporation of cortisol binding protein. Hydrocortisone binds 
both to albumin and to cortisol binding globulin (CBG) in human 
plasma. Data on human cortisol binding globulin expression in males 
and females were collected from the literature (see Supplementary Data 
– Section 2 for references). A meta-analysis was performed and the 
calculated weighted mean and CV for males (n=323) and females 
(n=235) were 0.751µM (cv = 14%) and 0.872 µM (cv = 19%), 
respectively. 
2.1.2.3. Ontogeny of CBG. Data on the ontogeny of CBG was taken from 
the literature (see Supplementary Data – Section 3 for references), with a 
total of 642 observed data points included in the analysis (Supplemen-
tary Figure 1). The fraction of adult expression with age was 0.22, 0.49, 
0.57, 0.7, 0.82, 0.95 and 1 at 0, 0.08, 0.5, 3, 5, 7, and 18 years, 
respectively. The ontogeny profile was entered into the Simcyp Simu-
lator as a scalar for the adult values. 
2.1.2.4. Metabolism of hydrocortisone and ontogeny of major pathways. 
The elimination of hydrocortisone is complex (see Supplementary 
Figure 2) and was grouped into major metabolic routes for the purpose 
of the current PBPK models. Active hydrocortisone (cortisol) is con-
verted to inactive cortisone by the enzyme 11β-hydroxysteroid dehy-
drogenase 2 (11β-HSD2)(Walker and Seckl, 2001). The other major 
elimination enzyme is 5α-reductase and there is a minor contribution 
from cytochrome P450 3A (CYP3A4) in the 6β hydroxylation of cortisol. 
Other metabolic pathways, 20β-oxoreductase and 5β-reductase are 
lumped together as ‘Additional metabolism’. 
The ontogeny of 11β-HSD2 was derived based on urinary cortisone to 
cortisol ratios (Rodgers and Rowland, 2006), and that for 5α-reductase 
from urinary allo-Tetrahydrocortisol/Tetrahydrocortisol ratios (Wudy 
et al., 2007). The sources of information and equations describing 
11β-HSD2 and 5α-reductase ontogeny profiles are listed in the Supple-
mentary data – Section 3 and the final ontogeny profiles are shown in 
Supplementary Figure 3. The CYP3A4 ontogeny profile in the Simcyp 
Simulator has been described previously (Salem et al., 2014), and no 
ontogeny was assumed for the additional clearance pathways. 
2.1.2.5. Drug parameters used in the models. Immediate- and modified- 
release model input parameters and their sources of information are 
summarized in Supplementary Table 2. The formulation and absorption 
aspects incorporated into the PBPK models are described in more detail 
in the Supplementary data – Section 1. 
2.1.2.6. Plasma protein binding. For the immediate-release model, a 
non-linear free fraction of hydrocortisone in plasma (fu), reflecting 
binding to both albumin and CBG, was calculated as described in the 
Supplementary Information – Sections 4 and 5. For the modified-release 
model the reference protein [P]ref value for albumin was 45 g/L (Simcyp 
Simulator default) and that for CBG was 0.41 µM, taken from the 
immediate-release multi-particulate study Infacort-002, since CBG was 
not in the modified-release clinical studies. 
2.1.2.7. Incorporating hydrocortisone metabolic data into PBPK model. 
The fraction metabolised by the different metabolic pathways is shown 
in Supplementary Table 3. Values were calculated based on available 
mass balance data for total metabolites (including glucuronides) and 
unchanged drug. Because the 11β-HSD2 and 5α-reductase enzymes are 
not available in the Simulator, two of the UDP-glucuronosyltransferase 
enzymes were used as surrogates for these enzymes. Relative enzyme 
expression was used in the simulations and for the paediatric simula-
tions, the relevant ontogeny functions were applied for 11β-HSD2 and 
5α-reductase (See Supplementary Information - Section 6). The retro-
grade model was used to generate initial intrinsic clearance values for 
CYP3A4, 11β-HSD2, 5α-reductase and an additional clearance based on 
a weighted mean fixed fraction unbound of 0.066 and a CLiv value of 
20L/h. 
2.1.2.8. Distribution. The minimal PBPK model with a single adjusting 
compartment (SAC) was used to describe the distribution of hydrocor-
tisone. This model, akin to a 2-compartmental PK model plus liver 
compartment, gave similar results to using a full PBPK model for the 
immediate release formulation (data not shown). This model, but not 
full PBPK, allows the added flexibility of simulating the effects of 
changing fu on volume of distribution. In the immediate-release model, 
the volume of distribution of hydrocortisone was dynamically linked to 
changes in fu during the simulation. However, during the simulation of 
modified-release dosing in paediatrics, this setting caused an instability 
in the ODE (ordinary differential equation) solver output. Therefore, for 
modified-release modelling a fixed volume of distribution was applied. 
Outputs were checked for both a fixed and concentration-dependent 
volume of distribution and it was found that fixing the volume had no 
effect on the resulting simulations, so this was carried forward. 
2.1.3. Simulation of clinical studies 
All model development and verification simulations were run using 
virtual subjects matched as closely as possible with respect to age and 
sex to those in the corresponding actual studies (Supplementary Table 
1), and according to the same study designs. However, it should be noted 
that the healthy volunteer virtual adult and the healthy virtual paedi-
atric populations within Simcyp were used for all simulations, whereas 
the clinical studies had a mixture of healthy volunteers and CAH pa-
tients. At this time little is known of any physiological differences be-
tween healthy and CAH patients that may affect PK. For the published 
clinical studies, data from more than one study were combined into a 
single study design; more detail of the specific trial designs within the 
simulator are given in the Supplementary data – Section 7. The dose 
units for simulations were those in the clinical studies. 
2.1.3.1. Paediatric model application – modified-release formulation. The 
developed modified-release model was used within the Simcyp Paedi-
atric Simulator to simulate single and multiple dose pharmacokinetics in 
the age range of 12 to 18 years at doses based on body weight and body 
surface area. These paediatric simulation results were then compared 
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with adult simulations at the same dose. In the single dose cases, sim-
ulations were 24 hours in duration, with drug administration in the 
morning. In the multiple dose cases, simulations were 72 hours in 
duration, with drug administration at 2300 h and 0700 h each day, 
starting with the first dose of the modified-release formulation at 2300 h 
on day 1 of the simulation (actual day 2 of clinical study). 
For the first paediatric simulations, doses were calculated using the 
body surface areas of the adult subjects (CAH patients) in the multiple- 
dose clinical study. The doses of 20 mg and 10 mg were divided by each 
individual’s body surface area (calculated using the DuBois formula) to 
obtain BSA-based doses 11.6 and 5.8 mg/m2, respectively. 
Doses of 8 mg/m2 in the evening and 4 mg/m2 in the morning (12 
mg/m2 over 24 hours) were also used in the model application simu-
lations after being rounded to available capsule size combinations. This 
dose is in keeping with current guidelines on the treatment of CAH 
(Speiser et al., 2018). These simulations were run using the Simcyp 
Paediatric Simulator in six month age bands ranging from 12 to 18.5 
years old. 
2.1.4. Data analysis 
Predicted and observed concentration-time data was compared using 
a visual predictive check, the number of observed data points within the 
5th and 95th predicted range were considered. For PK parameters the 
ratio of predicted to observed values was determined. 
A good prediction was defined as between 0.8 and 1.25-fold of the 
observed (bioequivalence criteria based on ± 20% difference), reason-
able prediction as between 0.67 and 1.5-fold of the observed and 
acceptable prediction as between 0.5 and 2-fold of the observed. Though 
there is no universally agreed-upon scale of PBPK model prediction 
quality, these ranges are often used (Abduljalil et al., 2014). 
3. Results 
3.1. Simulation of previously published adult hydrocortisone PK studies 
The results of the simulation of published clinical hydrocortisone PK 
studies following intravenous (IV) and oral administration are shown in 
Table 1. For all three IV and 6 out of 7 oral studies the predicted AUC0- 
inf was within 0.8 to 1.25-fold of observed. For the 5 and 10mg oral dose 
simulations the Cmax was 0.79-fold in both cases and predicted Tmax was 
1.2 vs 0.7 or 0.8 hours. The predicted PK parameters for the 20mg dose 
were in close agreement with the four clinical studies published. For the 
30mg oral dose, the AUC was 1.42-fold of observed. 
3.2. Adult immediate-release multi-particulate formulation studies 
Figure 2 shows the results of the simulation of the oral Infacort-001 
and Infacort-002 PK studies and a summary of PK parameter results is 
given in Table 1. For all simulations at the different doses, the pre-
dictions were good; the majority (90%) of individual observed 
concentration-time data were within the simulated 5th and 95th 
percentile. The predicted/observed AUC ratio was within 0.8 to 1.25- 
fold in for all Infacort® studies, but at the lower doses of 0.5 to 2mg 
there was some slight under-prediction of Cmax. Overall, the predicted/ 
observed Cmax ratio was within 0.8 to 1.25-fold in 3 out of 5 cases and 
always within 2-fold. Simulated median Tmax values were slightly longer 
than observed, however there was overlap in the observed and predicted 
ranges. The model successfully simulated the known non-linear cortisol 
binding globulin (CBG) binding of hydrocortisone, as reflected in Sup-
plementary Figure 4. 
3.3. Paediatric immediate-release multi-particulate formulation studies 
Figures 3A-C show the predicted concentration-time profile 
Figure 2. Predicted concentration-time profiles (mean—black lines; 5th and 95th percentiles—grey lines) and observed individual values (open circles) of immediate- 
release hydrocortisone in healthy dexamethasone-suppressed adults for Infacort-001 and Infacort-002 clinical studies. A) 0.5 mg; B) 2 mg; C) 5 mg; D) 10 mg; E) 
20 mg 
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compared to the clinical trial data for paediatric cohorts 1 to 3 on a log 
scale, LHS with modelled ontogeny for 11β-HSD2 and 5α-reductase, and 
RHS with no modelled ontogeny. As the observed data were sparse data, 
there are no calculated PK parameters. In all cases assuming ontogeny, 
80 % of the observed data are within the predicted 5th and 95 percentiles 
compared to 68% assuming no ontogeny. For cohort 1, 2 to 4.7y 
(Figure 3A) the observed elimination rate appears faster than predicted. 
For cohorts 2 and 3, 0.3 to 1.8y (Figure 3B) and 0.044 to 0.071 y 
(Figure 3C) the elimination rate appears reasonably predicted. 
3.4. Adult modified-release formulation studies 
A comparison of simulated and observed plasma concentrations of 
cortisol following a single oral 20 mg dose of the modified-release 
formulation in the fasted state are shown in Figure 4A. Associated 
mean Cmax and AUC(0,24) values are compared in Table 1. The simulated 
mean AUC values were within 1.2-fold of the observed data. Due to the 
variability in the observed Tmax values in modified release, the simulated 
Cmax of the mean cortisol plasma concentration profile (487 nmol/L) 
was lower than the mean of individual observed Cmax values (708 nmol/ 
L). Whilst the simulated mean plasma cortisol concentrations were in 
reasonable agreement with the mean observed plasma cortisol concen-
trations, the mean of observed individual Cmax values was approxi-
mately 1.5-fold higher than the corresponding simulated value. The 
geometric mean of the fraction absorbed was 0.97 for this and all 
modified-release and immediate-release multi-particulate adult simu-
lations. Eighty-six percent of observed concentrations were within the 
5th and 95th percentiles of the simulated population. 
A comparison of simulated and observed plasma concentrations of 
cortisol following a single oral 20 mg dose of the modified-release 
formulation in the fasted state from a different study are shown in 
Figure 4B in which individual concentrations for the observed and mean 
and 5th and 95th percentiles of the simulated population are displayed. 
Associated mean Cmax and AUC(0,24) values are compared in Table 1. The 
simulated mean AUC(0-24) was a very close match to the observed value, 
whereas the mean Cmax was somewhat under-predicted (simulated Cmax 
was 78% of the observed Cmax). The simulated median Tmax was also 
earlier than the corresponding observed value (simulated Tmax was 77% 
of the observed Tmax). Eighty-eight percent of observed concentrations 
were within the 5th and 95th percentiles of the simulated population. 
A comparison of simulated and observed plasma concentrations of 
cortisol on the third day following oral dosing of a 20 mg dose of the 
modified-release formulation in the evening and 10 mg the following 
morning (8 hour interval) for 3 days in CAH patients are shown in 
Figure 4C. Individual concentrations for the observed and mean and 5th 
and 95th percentile of the simulated population are displayed. Associ-
ated geometric mean Cmax and AUC values are compared in Table 1. The 
simulated mean AUC and Cmax values were within 1.1-fold of the 
observed values and 80% of the observed data points were within the 5th 
and 95th percentiles of the simulated population. 
A comparison of simulated and observed plasma concentrations of 
cortisol following a single oral 20 mg dose of the modified-release 
formulation in the fed state are shown in Figure 4D. Associated mean 
Cmax and AUC(0,24) values are compared in Table 1. The simulated mean 
Figure 3. Predicted concentration-time profiles (mean—black lines; 5th and 95th percentiles—grey lines) and observed individual values (open circles) of immediate- 
release hydrocortisone in paediatric patients for Infacort-003 clinical study. The described ontogeny is incorporated in the left-hand graphs and no ontogeny assumed 
in the graphs on the right. A) 0.16 mg/kg given to children 2 to 4.7 y.o. (Cohort 1); B) 0.22 mg/kg given to infants 0.3 to 1.8 y.o. (Cohort 2); C) 0.53 mg/kg given to 
neonates 0.044 to 0.071 y.o. (Cohort 3). 
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Figure 4. A) Mean simulated (line) and observed (open circles, baseline adjusted individual data points - DIUR-004 clinical study) plasma cortisol concentrations 
following a single oral dose of modified release hydrocortisone (20 mg) to fasted healthy individuals. The dashed lines represent 5th and 95th percentiles of the 
simulated population (n = 180). B) Mean simulated (line) and observed (open circles, baseline adjusted individual data points - DIUR-008 clinical study) plasma 
cortisol concentrations following a single oral dose of modified release hydrocortisone (20 mg) to fasted healthy individuals. The dashed lines represent 5th and 95th 
percentiles of the simulated population (n = 240). C) Mean simulated (line) and observed (open circles, baseline adjusted individual data points - DIUR-003 clinical 
study) plasma cortisol concentrations on the 3rd day after oral dosing of 20 mg modified release hydrocortisone in the evening and 10 mg modified release hy-
drocortisone the following morning (8 hour interval) for 3 days in CAH patients. The dashed lines represent 5th and 95th percentiles of the simulated population (n =
160). D) Mean simulated (lines) and observed (circles, baseline adjusted, individual data points - DIUR-004 clinical study) plasma cortisol concentrations following a 
single oral dose of modified release hydrocortisone (20 mg) to fed healthy individuals. The dashed lines represent 5th and 95th percentiles of the simulated pop-
ulation (n = 180). 
Table 2 
Results for simulations of a single 0.3 mg/kg dose as well as multiple dosing of 0.3 mg/kg in the evening and 0.15 mg/kg in the morning of the modified-release 
formulation in virtual adolescents (ages 12 to 18 years). Cmax and AUC values are geometric means, Tmax.are median and range.  
Modified-release dosing regimen Population Cmax nmol/L AUC(0-24h) nmol*h/L Tmax h 
0.3 mg/kg orally as a single dose Paediatric 564±166 2940±984 3.6 (1.3 to 6.8)  
Adult 543±147 2992±901 3.9 (1.2 to 8.1)  
P/A 1.04 0.98 0.92 
Modified-release dosing regimen Population Cmax(48-56h) nmol/L AUC(48-72h) nmol*h/L Tmax h 
0.3 mg/kg q23:00h, 0.15 mg/kg q07:00h x 3 days Paediatric 581±157 4631±1436 -  
Adult 593±166 5012±1453 -  
P/A 0.98 0.92 - 
Modified-release dosing regimen Population Cmax nmol/L AUC(0-24h) nmol*h/L Tmax h 
11.6 mg/m2 orally as a single dose Paediatric 608±170 3194±958 3.5 (1.3 to 6.8)  
Adult 529±138 2908±814 3.9 (1.1 to 8.1)  
P/A 1.15 1.10 0.90 
Modified-release dosing regimen Population Cmax(48-56h) nmol/L AUC(48-72h) nmol*h/L Tmax h 
11.6 mg/m2 q23:00h, 5.8 mg/m2 q07:00 × 3days Paediatric 617±167 5173±1500 -  
Adult 588±165 4965±1440 -  
P/A 1.05 1.04 -  
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AUC was within 1.2-fold of the observed data and simulated mean Cmax 
within 1.25-fold of observed. However, though the mean simulated Tmax 
was within 2-fold of observed (4.2 hours simulated vs. 6.8 hours 
observed), it was significantly lower, failing to capture the observed 
significant increase in Tmax in the fed state as compared with the fasted. 
In total 65% of the observed data points were within the 5th and 95th 
percentiles of the simulated population. 
3.5. Adolescent modified-release formulation simulations 
Results for simulations of a single 0.3 mg/kg dose as well as multiple 
dosing of 0.3 mg/kg in the evening and 0.15 mg/kg in the morning of the 
modified-release formulation in virtual adolescents (ages 12 to 18 years) 
are shown in Table 2. Following body weight-based dosing, mean Cmax, 
Tmax, and AUC in adolescents were within 8% of adult values. Results for 
simulation of a single 11.6 mg/m2 dose as well as multiple dosing of 11.6 
mg/m2 in the evening and 5.8 mg/m2 in the morning of the modified- 
release formulation in virtual adolescents ages 12 to 18 years are 
shown in Table 2. After this body surface area-based dosing, mean Cmax, 
Tmax, and AUC in adolescents were within 15% of adult values. A 
comparison of the simulated mean plasma concentrations in adults and 
adolescents is shown in Figure 5. The recommended dose for adolescents 
is between 10-15 mg/m2 (Speiser et al., 2018), we have therefore also 
simulated the mid-range daily dose of 12 mg/m2 and how this would be 
administered in the unit dose of modified-release hydrocortisone 
providing a physiological Cmax and AUC (Table 3). 
4. Discussion 
We have built a PBPK model for hydrocortisone and tested it against 
the published literature and clinical trials using novel formulations of 
immediate-release hydrocortisone (Infacort®) and modified-release 
hydrocortisone (Chronocort®). The PBPK model predicted PK parame-
ters in adults and children across hydrocortisone dose ranges 0.5 to 20 
mg. The model captured the adult modified-release PK data after single 
and multiple dosing, provided predictions of PK in adolescents 12 to 18- 
years and allowed us to generate dosing regimens for adolescents using 
modified-release hydrocortisone. 
In recent years there has been a renewed interest in the use of PBPK 
modelling in drug development, specifically in the area of drug-drug 
interaction prediction; however, use in paediatric and other areas of 
drug development is increasing (Jamei, 2016; Sato et al., 2017). Pae-
diatric PBPK has been used to determine the age related doses for clin-
ical trials (Leong et al., 2012; Rioux and Waters, 2016), drug-drug 
interactions (Olafuyi et al., 2017), formulation bridging (Johnson 
et al., 2014) and study design (Dumont et al., 2013). There are few 
published examples of PBPK simulations for humans involving 
replacement of endogenous substrates such as hormones (Li et al., 2014; 
Figure 5. A) Simulated mean (n = 180) plasma cortisol concentrations after a single oral dose of 11.6 mg/m2 modified release hydrocortisone in children aged 12 to 
18 years (solid line) and in adults (dotted line). B) Simulated mean (n = 160) plasma cortisol concentrations on the 3rd day after oral dosing of 11.6 mg/m2 modified 
release hydrocortisone in the evening and 5.8 mg/m2 modified release hydrocortisone the following morning (8 hour interval) for 3 days in children aged 12 to 18 
years (solid line) and in adults (dotted line). 
Table 3 
Predicted PK parameters in adolescents by age band after clinically proposed BSA-based dosing of 12 mg/m2 per day Table 1. Geometric means of BSA-based dosing of 
12 mg/m2 per day simulations in virtual adolescents broken down by 6-month age bands and rounded to the nearest capsule size doses of modified-release hydro-
cortisone. Cmax and AUC values are geometric means.  
Age (years) Equivalent 
BSA (m2) 
Calculated PM dose 
based on BSA (mg) (8 
mg/m2) 
Calculated AM dose 













12 – 12.5 1.3 10.4 5.2 10/5 506.4 329.2 2187 1765 
12.5 – 13 1.3 10.4 5.2 10/5 483.8 313 2088 1683 
13 – 13.5 1.4 11.2 5.6 10/5 463.4 298.4 1999 1609 
13.5 – 14 1.4 11.2 5.6 10/5 447.6 287.1 1931 1553 
14 – 14.5 1.5 12 6 10/5 434.3 277.6 1874 1507 
14.5 – 15 1.5 12 6 10/5 417.7 266.1 1801 1448 
15 – 15.5 1.6 12.8 6.4 15/5 523.7 276.8 2321 1565 
15.5 – 16 1.6 12.8 6.4 15/5 512.1 270 2268 1529 
16 – 16.5 1.6 12.8 6.4 15/5 502.2 264.2 2220 1505 
16.5 - 17 1.6 12.8 6.4 15/5 493.6 259.1 2181 1478 
17 – 17.5 1.6 12.8 6.4 15/5 489.5 256.7 2162 1465 
17.5 – 18 1.6 12.8 6.4 15/5 485.1 254.1 2142 1452 
18 – 18.5 1.6 12.8 6.4 15/5 482.9 252.9 2132 1448  
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Nakada et al., 2018). This is the first time a PBPK model has been 
developed for hydrocortisone, an endogenous compound, and the model 
incorporates the known complexities in hydrocortisone disposition. 
Thus, the model includes systems information to account for non-linear 
binding to cortisol binding protein, metabolism by 11β-HSD2 and 
5α-reductase, cortisol metabolism by 20β-oxo-reductase and 5β-reduc-
tase and how these parameters develop with age. 
Overall results from the simulations of published adult immediate- 
release oral and IV hydrocortisone PK studies and adult immediate- 
release multi-particulate studies indicate that the model performs well 
over the dose range 5 to 20 mg for IV administration and 0.5 to 30 mg for 
oral administration of immediate-release hydrocortisone. There is some 
under-prediction of Cmax particularly in 0.5 mg and 2 mg single dose 
immediate-release multi-particulate formulation simulations. It is not 
clear what the source of error is, but it may be a consequence of inac-
curacies in defining the non-linear protein binding effects on volume of 
distribution or a slower absorption rate coming through the absorption 
model. However, for 5 mg and above the predicted/observed AUC and 
Cmax ratios are within the tight range of 0.8 to 1.04-fold, these are the 
dose levels of more therapeutic interest in the adolescent and adult 
population. In general, the 5th and 95th percentiles for the simulations 
capture the variability in observed PK, although there is some evidence 
that variability in patient groups with primary or secondary adrenal 
insufficiency is higher compared to healthy volunteers (Werumeus 
Buning et al., 2017). 
The paediatric immediate-release multi-particulate formulation 
simulations reasonably captured the concentration-time profiles down 
to neonates around 2 weeks of age. For the two younger age groups of 
neonates (less than 1 month old) and infants (1-24 month old), the 
simulated developmental patterns for 11β-HSD2 and 5α-reductase 
appear reasonable in relation to the results. However, for the older age 
group between 24 months and 6 years the observed elimination appears 
to be slightly faster than that predicted, this could be due to over-
expression of other steroid metabolizing enzymes, placed together as 
‘additional clearance’ and assumed to have no ontogeny in this age 
group, or misspecification of the applied ontogeny for 11β-HSD2 or 5α- 
reductase. The ontogeny of 11β-HSD2 and 5α-reductase are derived 
from urinary cortisone/cortisol and allo-Tetrahydrocortisol/ 
Tetrahydrocortisol ratios (Wudy et al., 2007). Whilst these ratios may 
need correcting for age related changes in renal function and also one 
minus fraction reabsorbed, there is little evidence regarding the 
ontogeny of the latter and the assumption was made that both of these 
factors cancel out. The simulations assuming no ontogeny for all en-
zymes resulted in poorer prediction of the observed data and give 
further evidence for over-expression of cortisol metabolizing enzymes in 
the younger age groups. 
Simulations of the adult modified-release PK studies showed that the 
final model recovered the observed plasma cortisol concentrations well 
in both single and multiple dosing scenarios. For the 20 mg single-dose 
(healthy volunteers) simulations in the fasted state, the simulated mean 
AUC values were within 1.1-fold of the observed data. Due to the ex-
pected variability in the observed Tmax values from modified-release, the 
observed Cmax of the mean cortisol plasma concentration profile (487 
nmol/L) was lower than the mean of individual Cmax values (708 nmol/ 
L). Whilst the simulated mean plasma cortisol concentrations were in 
reasonable agreement with the mean observed plasma cortisol concen-
trations, the mean of observed individual Cmax values was 1.5-fold 
higher than the corresponding simulated value. Single-dose simula-
tions of 20 mg of the modified-release formulation in healthy volunteers 
as in study DIUR-008 yielded an exposure (as measured by AUC0-24h) 
nearly identical to that observed. Cmax and Tmax were slightly under-
predicted by the model but well within 2-fold of the observed geometric 
mean parameter values. For the 20 mg/10 mg multiple dosing study 
simulations in the fasted state, the simulated mean AUC and Cmax values 
were within 1.1-fold of the observed data. In the single-dose simulation 
of 20 mg modified-release in the fed state, the simulated mean AUC and 
Cmax values were within 1.25-fold of the observed data but the Tmax was 
less well predicted, though with the mean still within 2-fold of observed. 
After calculation of mg/kg and mg/m2 doses roughly equivalent to 
20 mg and 10 mg of the modified-release formulation in adults, simu-
lations were performed in a virtual paediatric population aged 12 to 18 
and results compared to equivalent doses simulated in adults. The re-
sults showed minimal difference in Cmax, Tmax, and AUCs between adults 
and children. These simulation results suggest that dosing of the 
modified-release formulation based on either body weight (mg/kg) or 
body surface area (mg/m2) will yield predictable pharmacokinetics in 
paediatric populations. The hydrocortisone doses recommended by 
guidelines for adolescents with CAH are 10–15 mg/m2 per day (Speiser 
et al., 2018), and the model was used to predict a clinically appropriate 
dosing regimen for adolescents based on a daily dose of 12 mg/m2. 
The limitations of our model include not inputting the circadian 
variation in CBG in the model, however a recent PK study by Melin et al. 
(2019) concluded: ‘the difference in cortisol exposure is <11% between 
times of highest and lowest CBG concentrations; therefore hydrocorti-
sone dose adjustment based on time of dosing is not required’. There are 
a number of assumptions in the current PBPK models related to the 
metabolism of hydrocortisone. Active hydrocortisone (cortisol) is 
metabolised to inactive cortisone in vivo by the enzyme 11β-HSD2 and 
the latter converted back to cortisol as needed by 11β-HSD1. Repre-
sentation of the metabolic fate of hydrocortisone required some 
simplification of the pathways involved. In particular, the interconver-
sion of cortisol and cortisone was subsumed in the net forward reaction 
to the latter compound. Lumping of pathways accounting for 36.6% of 
total metabolism assumed no ontogeny has been discussed. One other 
assumption is that most of the metabolism is occurring in the liver with 
some in the kidney, in reality hydrocortisone is metabolised in a number 
of tissues (Walker and Seckl, 2001). This will not change the overall 
results but is less mechanistic than what is actually occurring in vivo. 
In conclusion, the current models, verified using a large amount of 
available clinical data, account for the complexities in the PK of hy-
drocortisone. These models are potentially useful tools for understand-
ing significant covariates within clinical studies and for dose 
extrapolation into other paediatric age ranges, other ethnic groups and 
between formulations. 
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